TNDM:NSD-Tandem Diabetes Care Inc (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 42.45

Change

0.00 (0.00)%

Market Cap

USD 2.89B

Volume

1.35M

Analyst Target

USD 120.13
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 26.96B
PODD Insulet Corporation

N/A

USD 16.27B
BRKR Bruker Corporation

N/A

USD 10.70B
MASI Masimo Corporation

N/A

USD 7.12B
TMDX TransMedics Group Inc

N/A

USD 5.50B
PRCT Procept Biorobotics Corp

N/A

USD 4.13B
AXNX Axonics Modulation Technologie..

N/A

USD 3.55B
QDEL Quidel Corporation

N/A

USD 3.06B
LIVN LivaNova PLC

N/A

USD 2.85B
UFPT UFP Technologies Inc

N/A

USD 2.49B

ETFs Containing TNDM

DDOC:XETRA Global X Telemedicine & D.. 4.06 % 0.00 %

N/A

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.06 % 0.00 %

N/A

USD 4.62M
EDOC:SW Global X Telemedicine & D.. 4.04 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 4.01 % 0.00 %

N/A

USD 3.87M
EDOG:LSE Global X Telemedicine & D.. 4.01 % 0.00 %

N/A

USD 0.23M
EDOC Global X Telemedicine & D.. 3.95 % 0.00 %

N/A

USD 0.05B
SSLY Syntax Stratified SmallCa.. 0.69 % 0.00 %

N/A

USD 0.01B
SLIM 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1,335.09% 84% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,335.09% 84% B 93% A
Trailing 12 Months  
Capital Gain 1,943.81% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,943.81% 88% B+ 94% A
Trailing 5 Years  
Capital Gain 658.31% 89% A- 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 658.31% 89% A- 92% A
Average Annual (5 Year Horizon)  
Capital Gain 1.17% N/A N/A 46% F
Dividend Return 1.17% N/A N/A 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 110.77% N/A N/A 16% F
Risk Adjusted Return 1.06% N/A N/A 39% F
Market Capitalization 2.89B 93% A 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.